Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …

Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

5529 Background: We previously reported results of a phase 2 study of concurrent
cetuximab, a chimeric monoclonal antibody directed against the epidermal growth factor …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Purpose Despite treatment, prognosis of unresectable squamous cell carcinoma of the head
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …

Objective: Whether or not cisplatin and cetuximab are similarly effective in improving
outcomes when added to radiation therapy (RT) in squamous cell carcinoma of the head …

Purpose This study describes the long-term survival and toxicity outcomes of a multicenter
randomized phase 2 trial comparing radiation therapy (RT) plus cisplatin (CDDP) or …

5513 Background: The standard treatment options for LASCCHN are cCHT+ RT or CET+
RT. Strategies to improve the efficacy with the integration of induction chemotherapy are …

Objective. To review the current state of the data on the use of cetuximab in head and neck
squamous cell carcinoma (HNSCC). Data Sources. The National Center for Biotechnology …

Introduction The purpose of this study was to evaluate the clinical efficacy in our daily
practice, outside clinical trials, of cetuximab plus radiotherapy in a majority of treatment …